CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6103 participants.

Also called NCT01243424

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01243424
  • EudraCT 2009-013157-15
Other papers using this trial's data
  • Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study Diabetologia, 2021-06 DOI, PubMed 33559704, PMC8099814 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Finland, France, Georgia, Germany, Greece, Hong Kong SAR China, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01243424. Randomized; double masking; primary purpose treatment. Start 2010-11-11 (actual); primary completion 2018-08-21 (actual). Results posted on 2020-01-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
linagliptin
Intervention (Drug)
glimepiride
Intervention (Drug)
linagliptin placebo
Intervention (Drug)
glimepiride placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01243424
Content hash
8fe484984049d26d3fdc4c08c311413375c22f6f46beec399689a2b53ba09cc7